{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:17:04Z","timestamp":1790821024722,"version":"4.1.0"},"reference-count":73,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>BCC is the most prevalent form of skin cancer, characterized by diverse clinical and pathological subtypes ranging from indolent to highly aggressive forms. While the majority of BCC cases are treated effectively with surgery or local therapies, locally advanced BCC (laBCC) and metastatic BCC (mBCC) pose significant therapeutic challenges. Recent advances in HHIs and immunotherapy have transformed the treatment landscape in such cases. However, resistance and intolerance to these treatments necessitate alternative approaches, including chemotherapy. Platinum-based agents such as cisplatin and carboplatin have shown limited efficacy but remain viable options in rapidly progressive cases. Among the therapeutic innovations to be explored, further lines of immunotherapy as well as combination therapies involving immunotherapy and targeted therapy have been proposed. This review synthesizes the current understanding about BCC subtypes, risk stratification, and emerging treatments, with a particular focus on laBCC and mBCC.<\/jats:p>","DOI":"10.3390\/cancers17060993","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T15:24:56Z","timestamp":1742225096000},"page":"993","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Basal Cell Carcinoma: An Old Friend with Multiple Faces"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-6841","authenticated-orcid":false,"given":"Maria Chiara","family":"Sergi","sequence":"first","affiliation":[{"name":"Unit\u00e0 Operativa Complessa di Oncologia Medica, Ospedale \u201cMons. A.R. Dimiccoli\u201d Asl BT, Viale Ippocrate, 15, 70051 Barletta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ambrogio","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5116-2484","authenticated-orcid":false,"given":"Mario","family":"Della Mura","sequence":"additional","affiliation":[{"name":"Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8458-8648","authenticated-orcid":false,"given":"Joana","family":"Sorino","sequence":"additional","affiliation":[{"name":"Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0325-4316","authenticated-orcid":false,"given":"Gerardo","family":"Cazzato","sequence":"additional","affiliation":[{"name":"Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113254","DOI":"10.1016\/j.ejca.2023.113254","article-title":"European Consensus-Based Interdisciplinary Guideline for Diagnosis and Treatment of Basal Cell Carcinoma-Update 2023","volume":"192","author":"Peris","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2019.06.003","article-title":"Diagnosis and Treatment of Basal Cell Carcinoma: European Consensus-Based Interdisciplinary Guidelines","volume":"118","author":"Peris","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.det.2022.07.005","article-title":"Basal Cell Carcinoma","volume":"41","author":"Heath","year":"2023","journal-title":"Dermatol. Clin."},{"key":"ref_4","unstructured":"McDaniel, B., Badri, T., and Steele, R.B. (2025). Basal Cell Carcinoma. StatPearls, StatPearls Publishing."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Attal, Z.G., Shalata, W., Soklakova, A., Tourkey, L., Shalata, S., Abu Saleh, O., Abu Salamah, F., Alatawneh, I., and Yakobson, A. (2024). Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options. Biomedicines, 12.","DOI":"10.3390\/biomedicines12071448"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chen, O.M., Kim, K., Steele, C., Wilmas, K.M., Aboul-Fettouh, N., Burns, C., Doan, H.Q., Silapunt, S., and Migden, M.R. (2022). Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14153720"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2133.2012.11090.x","article-title":"Occupational skin cancer induced by ultraviolet radiation and its prevention: Occupational skin cancer induced by UV radiation","volume":"167","author":"Diepgen","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/jid.2012.431","article-title":"Trends in Basal Cell Carcinoma Incidence Rates: A 37-Year Dutch Observational Study","volume":"133","author":"Flohil","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"i1152","DOI":"10.1136\/bmj.i1152","article-title":"The AGREE Reporting Checklist: A tool to improve reporting of clinical practice guidelines","volume":"352","author":"Brouwers","year":"2016","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Work Group, Invited Reviewers, Kim, J.Y.S., Kozlow, J.H., Mittal, B., Moyer, J., Olencki, T., and Rodgers, P. (2018). Guidelines of Care for the Management of Basal Cell Carcinoma. J. Am. Acad. Dermatol., 78, 540\u2013559.","DOI":"10.1016\/j.jaad.2017.10.006"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/jdv.17467","article-title":"Position Statement on Classification of Basal Cell Carcinomas. Part 2: EADO Proposal for New Operational Staging System Adapted to Basal Cell Carcinomas","volume":"35","author":"Grob","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1111\/ajd.12459","article-title":"Metastatic Basal Cell Carcinoma: Case Series and Review of the Literature","volume":"58","author":"Tang","year":"2017","journal-title":"Australas. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5826\/dpc.0502a02","article-title":"Infiltrating Basal Cell Carcinoma: A Stellate Peri-Tumor Dermatoscopy Pattern as a Clue to Diagnosis","volume":"5","author":"Pyne","year":"2015","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_14","unstructured":"WHO Classification of Tumours Editorial Board (2023). Skin Tumours, International Agency for Research on Cancer. [5th ed.]. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/64."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Brenn, T., Goodlad, J., and Mentzel, T. (2021). Nonmelanocytic Tumors of the Skin, American Registry of Pathology.","DOI":"10.55418\/9781933477121"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cocuz, I.G., Popelea, M.C., Niculescu, R., Manea, A., Sab\u0103u, A.-H., Tinca, A.-C., Szoke, A.R., Budin, C.E., Stoian, A., and Morariu, S.H. (2024). Pathophysiology, Histopathology, and Differential Diagnostics of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma\u2014An Update from the Pathologist\u2019s Point of View. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042220"},{"key":"ref_17","unstructured":"Calonje, E., Brenn, T., Lazar, A., and McKee, P.H. (2012). McKee\u2019s Pathology of the Skin: With Clinical Correlations, W.B. Saunders Company. [4th ed.]."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.5858\/arpa.2017-0222-RA","article-title":"Histologic Mimics of Basal Cell Carcinoma","volume":"141","author":"Stanoszek","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"\u0218erb\u0103nescu, M.-S., Bung\u0103rdean, R.M., Georgiu, C., and Cri\u0219an, M. (2022). Nodular and Micronodular Basal Cell Carcinoma Subtypes Are Different Tumors Based on Their Morphological Architecture and Their Interaction with the Surrounding Stroma. Diagnostics, 12.","DOI":"10.3390\/diagnostics12071636"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jaad.2019.11.008","article-title":"Dermoscopic Features of Basal Cell Carcinoma and Its Subtypes: A Systematic Review","volume":"85","author":"Reiter","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.4103\/idoj.idoj_443_23","article-title":"Clear Cell Basal Cell Carcinoma\u2014A Rare Variant","volume":"15","author":"Agrawal","year":"2024","journal-title":"Indian Dermatol. Online J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4103\/0378-6323.158652","article-title":"Granular Cell Basal Cell Carcinoma: A Rare Variant","volume":"81","author":"Tichy","year":"2015","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_23","first-page":"51","article-title":"Infundibulocystic Basal Cell Carcinoma: Dermoscopic Findings and Histologic Correlation","volume":"4","year":"2014","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3892\/etm.2021.10982","article-title":"Basal Cell Carcinoma: Comprehensive Clinical and Histopathological Aspects, Novel Imaging Tools and Therapeutic Approaches (Review)","volume":"23","author":"Niculet","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_25","unstructured":"Sevensma, K.E., and Ramphul, K. (2025). Premalignant Fibroepithelial Tumor of Pinkus. StatPearls, StatPearls Publishing."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/DAD.0000000000001563","article-title":"Morphologic, Immunohistochemical, and Molecular Distinction Between Fibroepithelioma of Pinkus and \u201cFenestrated\u201d Basal Cell Carcinoma","volume":"42","author":"Lindeman","year":"2020","journal-title":"Am. J. Dermatopathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/1203475421996320","article-title":"Fibroepithelioma of Pinkus (FEP)","volume":"26","author":"Damani","year":"2022","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11864-019-0610-0","article-title":"Diagnosis and Management of Basal Cell Carcinoma","volume":"20","author":"Tanese","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/jdv.16597","article-title":"Sclerodermiform Basal Cell Carcinomas vs. Other Histotypes: Analysis of Specific Demographic, Clinical and Dermatoscopic Features","volume":"35","author":"Conforti","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1590\/abd1806-4841.20186699","article-title":"Sclerodermiform Basal Cell Carcinoma: How Much Can We Rely on Dermatoscopy to Differentiate from Non-Aggressive Basal Cell Carcinomas? Analysis of 1256 Cases","volume":"93","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/cup.13808","article-title":"Basal Cell Carcinoma with Perineural Invasion: A Prospective Study Examining Subtype, Tumor Surface Diameter, Invasion Depth, and Anatomic Site in 3005 Consecutive Cases","volume":"47","author":"Pyne","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Murgia, G., Denaro, N., Boggio, F., Nazzaro, G., Benzecry, V., Bortoluzzi, P., Passoni, E., Garrone, O., and Marzano, A. (2023). Basosquamous Carcinoma: Comprehensive Clinical and Histopathological Aspects, Novel Imaging Tools, and Therapeutic Approaches. Cells, 12.","DOI":"10.3390\/cells12232737"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/cup.13543","article-title":"Primary Cutaneous Biphasic Sarcomatoid Basal Cell Carcinoma with Myoepithelial Carcinoma Differentiation: A New Variant","volume":"46","author":"Nieto","year":"2019","journal-title":"J. Cutan. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/01.pas.0000208900.23483.ba","article-title":"Sarcomatoid Basal Cell Carcinoma\u2014Predilection for Osteosarcomatous Differentiation: A Series of 11 Cases","volume":"30","author":"Goh","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1346-8138.2003.tb00430.x","article-title":"Basal Cell Carcinoma with Sarcomatoid Features (Sarcomatoid Carcinoma): Report of a Case and Review of the Literature","volume":"30","year":"2003","journal-title":"J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/PAI.0000000000001002","article-title":"Does Immunohistochemistry Add to Morphology in Differentiating Trichoepithelioma, Desmoplastic Trichoepithelioma, Morpheaform Basal Cell Carcinoma, and Microcystic Adnexal Carcinoma?","volume":"30","author":"Mohanty","year":"2022","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_37","first-page":"e9211","article-title":"Surgical Margin of Excision in Basal Cell Carcinoma: A Systematic Review of Literature","volume":"12","author":"Quazi","year":"2020","journal-title":"Cureus"},{"key":"ref_38","first-page":"167","article-title":"Basal Cell Carcinoma: Pathogenesis, Epidemiology, Clinical Features, Diagnosis, Histopathology, and Management","volume":"88","author":"Marzuka","year":"2015","journal-title":"Yale J. Biol. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/PRS.0b013e3181ea450d","article-title":"What Is the Best Surgical Margin for a Basal Cell Carcinoma: A Meta-Analysis of the Literature","volume":"126","author":"Gulleth","year":"2010","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Di Maria, A., Barone, G., Ferraro, V., Tredici, C., Manara, S., De Carlo, C., Gaeta, A., and Confalonieri, F. (2023). Recurrence of Basal Cell Carcinoma Treated with Surgical Excision and Histopathological Analysis with Frozen Section Technique with Complete Margin Control (CMC-FS): A 15-Year Experience of a Reference Center. Cancers, 15.","DOI":"10.3390\/cancers15153840"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(04)17399-6","article-title":"Surgical Excision vs Mohs\u2019 Micrographic Surgery for Basal-Cell Carcinoma of the Face: Randomised Controlled Trial","volume":"364","author":"Smeets","year":"2004","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(08)70260-2","article-title":"Surgical Excision versus Mohs\u2019 Micrographic Surgery for Primary and Recurrent Basal-Cell Carcinoma of the Face: A Prospective Randomised Controlled Trial with 5-Years\u2019 Follow-Up","volume":"9","author":"Mosterd","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_43","first-page":"CD003412","article-title":"Interventions for Basal Cell Carcinoma of the Skin","volume":"11","author":"Thomson","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jid.2017.09.033","article-title":"Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma","volume":"138","author":"Jansen","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/09546634.2019.1638883","article-title":"Efficacy and Safety of Imiquimod 5% Cream for Basal Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trial","volume":"31","author":"Jia","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S1470-2045(13)70143-8","article-title":"Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: A single blind, non-inferiority, randomised controlled trial","volume":"14","author":"Arits","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e14476","DOI":"10.1111\/dth.14476","article-title":"Beyond Mohs Surgery and Excisions: A Focused Review of Treatment Options for Subtypes of Basal Cell Carcinoma","volume":"34","author":"Altun","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Christensen, E., M\u00f8rk, E., Foss, O.A., M\u00f8rk, C., Kroon, S., Dotterud, L.K., Helsing, P., Vatne, \u00d8., Skogvoll, E., and Mj\u00f8nes, P. (2024). New, Simplified versus Standard Photodynamic Therapy (PDT) Regimen for Superficial and Nodular Basal Cell Carcinoma (BCC): A Single-Blind, Non-Inferiority, Randomised Controlled Multicentre Study. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0299718"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Dika, E., Scarf\u00ec, F., Ferracin, M., Broseghini, E., Marcelli, E., Bortolani, B., Campione, E., Riefolo, M., Ricci, C., and Lambertini, M. (2020). Basal Cell Carcinoma: A Comprehensive Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155572"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/lary.20608","article-title":"Radiotherapy for Cutaneous Squamous and Basal Cell Carcinomas of the Head and Neck","volume":"119","author":"Mendenhall","year":"2009","journal-title":"Laryngoscope"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.oraloncology.2012.02.015","article-title":"Cutaneous Head and Neck Basal and Squamous Cell Carcinomas with Perineural Invasion","volume":"48","author":"Mendenhall","year":"2012","journal-title":"Oral. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/DSS.0000000000001225","article-title":"Treatment patterns, outcomes, and patient satisfaction of primary epidermally limited nonmelanoma skin cancer","volume":"43","author":"Drew","year":"2017","journal-title":"Dermatol. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gambini, D., Passoni, E., Nazzaro, G., Beltramini, G., Tomasello, G., Ghidini, M., Kuhn, E., and Garrone, O. (2022). Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response. Front. Med., 9.","DOI":"10.3389\/fmed.2022.893063"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 42-month analysis of the randomized Phase 2 BOLT study","volume":"182","author":"Dummer","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/j.jaad.2021.02.074","article-title":"Response to \u201cEfficacy of Sonidegib in Histologic Subtypes of Advanced Basal Cell Carcinoma: Results from the Final Analysis of the Randomized Phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) Trial at 42 Months\u201d","volume":"84","author":"Villani","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ungureanu, L., Vasilovici, A.F., Halm\u00e1gyi, S.-R., Trufin, I.I., Apostu, A.P., Prisecaru, M., and \u0218enil\u0103, S.C. (2024). Immunotherapy in Basal Cell Carcinoma. J. Clin. Med., 13.","DOI":"10.3390\/jcm13195730"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-017-0228-3","article-title":"Basal Cell Carcinoma: PD-L1\/PD-1 Checkpoint Expression and Tumor Regression after PD-1 Blockade","volume":"5","author":"Lipson","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: An open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"102037","DOI":"10.1016\/j.esmoop.2023.102037","article-title":"Guidelines for the Diagnosis and Treatment of Basal Cell Carcinoma: A GRADE Approach for Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology","volume":"8","author":"Queirolo","year":"2023","journal-title":"ESMO Open"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1001\/archderm.1990.01670360128037","article-title":"Complete Response of Metastatic Basal Cell Carcinoma to Cisplatin Chemotherapy: A Report on Two Patients","volume":"126","author":"Khandekar","year":"1990","journal-title":"Arch. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.1990.8.2.342","article-title":"Cisplatin-Based Chemotherapy in Advanced Basal and Squamous Cell Carcinomas of the Skin: Results in 28 Patients Including 13 Patients Receiving Multimodality Therapy","volume":"8","author":"Guthrie","year":"1990","journal-title":"JCO"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1445-1433.2004.03130.x","article-title":"Metastatic Basal Cell Carcinoma: Rapid Symptomatic Response to Cisplatin and Paclitaxel","volume":"74","author":"Jefford","year":"2004","journal-title":"ANZ J. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"16546","DOI":"10.1200\/jco.2007.25.18_suppl.16546","article-title":"Chemotherapy for Advanced and Recurring Basal Cell Carcinoma (BCC) with Docetaxel and Cisplatin","volume":"25","author":"Buarque","year":"2007","journal-title":"JCO"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jaad.2018.08.017","article-title":"Pembrolizumab for Advanced Basal Cell Carcinoma: An Investigator-Initiated, Proof-of-Concept Study","volume":"80","author":"Chang","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2022.09.013","article-title":"Safety and Efficacy of Nivolumab, an Anti-PD1 Immunotherapy, in Patients with Advanced Basal Cell Carcinoma, after Failure or Intolerance to Sonic Hedgehog Inhibitors: UNICANCER AcS\u00e9 NIVOLUMAB Trial","volume":"177","author":"Chevret","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S922","DOI":"10.1016\/j.annonc.2022.07.946","article-title":"820P Nivolumab (NIVO) +\/\u2212 Relatlimab (RELA) or Ipilimumab (IPI) for Patients (Pts) with Advanced Treatment-Na\u00efve or -Refractory Basal Cell Carcinoma (BCC)","volume":"33","author":"Schenk","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Zelin, E., Maronese, C.A., Dri, A., Toffoli, L., Di Meo, N., Nazzaro, G., and Zalaudek, I. (2022). Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. J. Clin. Med., 11.","DOI":"10.3390\/jcm11123364"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1158\/1078-0432.CCR-09-3136","article-title":"Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas","volume":"16","author":"Walter","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40425-018-0439-2","article-title":"Resistance to Anti-PD-1-Based Immunotherapy in Basal Cell Carcinoma: A Case Report and Review of the Literature","volume":"6","author":"Sabbatino","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1042\/EBC20230001","article-title":"The Role of IFN-\u03b3-Signalling in Response to Immune Checkpoint Blockade Therapy","volume":"67","author":"Wong","year":"2023","journal-title":"Essays Biochem."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Dollinger, E., Bergman, D., Zhou, P., Atwood, S.X., and Nie, Q. (2020). Divergent Resistance Mechanisms to Immunotherapy Explain Responses in Different Skin Cancers. Cancers, 12.","DOI":"10.1101\/2020.09.15.298182"},{"key":"ref_73","first-page":"509","article-title":"Increased Expression of TGF-Beta\/Smad Proteins in Basal Cell Carcinoma","volume":"12","author":"Gambichler","year":"2007","journal-title":"Eur. J. Med. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/6\/993\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:54:22Z","timestamp":1760028862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/6\/993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":73,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cancers17060993"],"URL":"https:\/\/doi.org\/10.3390\/cancers17060993","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]}}}